Modality
Gene Editing
MOA
BCMA ADC
Target
FXIa
Pathway
Amyloid
WilmsMeso
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ Aug 2026
Phase 1Current
NCT06909223
238 pts·Wilms
2023-01→2026-08·Active
238 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-034mo awayPh2 Data· Wilms
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Active
Catalysts
Ph2 Data
2026-08-03 · 4mo away
Wilms
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06909223 | Phase 1/2 | Wilms | Active | 238 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |